NCT04847141View on ClinicalTrials.gov

A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients

PHASE3TerminatedINTERVENTIONAL
Enrollment

465

Participants

Timeline

Start Date

April 28, 2021

Primary Completion Date

November 10, 2021

Study Completion Date

December 27, 2021

Conditions
COVID-19Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Infection
Interventions
BIOLOGICAL

C19-IG 20%

Anti-COVID-19 Immune Globulin (Human) 20%

DRUG

0.9% Sodium chloride

C19-IG 20% matching placebo

Trial Locations (12)

17002

CAP Maluquer Salvador, Girona

28021

Centro de Salud San Andrés, Madrid

28035

Centro de Salud Fuentelarreina, Madrid

28108

Centro de Salud Hacienda de Pavones Sureste, Madrid

Centro de Salud Isla de Oza Noroeste, Madrid

28801

Centro de Salud Nuestra Señora del Pilar, Alcalá de Henares

28933

Centro de Salud Presentación Sabio, Móstoles

43003

Hospital Sant Pau i Santa Tecla, Tarragona

08902

CAP Gornal, L'Hospitalet de Llobregat

08670

CAP Navàs, Navàs

08024

CAP Sant Fèlix, Sabadell

08015

CAP Manso, Barcelona

Sponsors
All Listed Sponsors
lead

Grifols Therapeutics LLC

INDUSTRY

NCT04847141 - A Study to Evaluate the Safety and Efficacy of C19-IG 20% in SARS-CoV-2 Infected Asymptomatic Ambulatory Outpatients | Biotech Hunter | Biotech Hunter